Global Meningococcal Group B Vaccine Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Meningococcal Group B Vaccine market size was valued at US$ 1082.9 million in 2023. With growing demand in downstream market, the Meningococcal Group B Vaccine is forecast to a readjusted size of US$ 1969.7 million by 2030 with a CAGR of 8.9% during review period.
The research report highlights the growth potential of the global Meningococcal Group B Vaccine market. Meningococcal Group B Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Meningococcal Group B Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Meningococcal Group B Vaccine market.
Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Meningococcal Group B Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Meningococcal Group B Vaccine market. It may include historical data, market segmentation by Type (e.g., Bexsero, Trumenba), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Meningococcal Group B Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Meningococcal Group B Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Meningococcal Group B Vaccine industry. This include advancements in Meningococcal Group B Vaccine technology, Meningococcal Group B Vaccine new entrants, Meningococcal Group B Vaccine new investment, and other innovations that are shaping the future of Meningococcal Group B Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Meningococcal Group B Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Meningococcal Group B Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Meningococcal Group B Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Meningococcal Group B Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Meningococcal Group B Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Meningococcal Group B Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Meningococcal Group B Vaccine market.
Market Segmentation:
Meningococcal Group B Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Meningococcal Group B Vaccine market?
What factors are driving Meningococcal Group B Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Group B Vaccine market opportunities vary by end market size?
How does Meningococcal Group B Vaccine break out type, application?
According to our LPI (LP Information) latest study, the global Meningococcal Group B Vaccine market size was valued at US$ 1082.9 million in 2023. With growing demand in downstream market, the Meningococcal Group B Vaccine is forecast to a readjusted size of US$ 1969.7 million by 2030 with a CAGR of 8.9% during review period.
The research report highlights the growth potential of the global Meningococcal Group B Vaccine market. Meningococcal Group B Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Meningococcal Group B Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Meningococcal Group B Vaccine market.
Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Meningococcal Group B Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Meningococcal Group B Vaccine market. It may include historical data, market segmentation by Type (e.g., Bexsero, Trumenba), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Meningococcal Group B Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Meningococcal Group B Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Meningococcal Group B Vaccine industry. This include advancements in Meningococcal Group B Vaccine technology, Meningococcal Group B Vaccine new entrants, Meningococcal Group B Vaccine new investment, and other innovations that are shaping the future of Meningococcal Group B Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Meningococcal Group B Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Meningococcal Group B Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Meningococcal Group B Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Meningococcal Group B Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Meningococcal Group B Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Meningococcal Group B Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Meningococcal Group B Vaccine market.
Market Segmentation:
Meningococcal Group B Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Bexsero
- Trumenba
- Other
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Pfizer
What is the 10-year outlook for the global Meningococcal Group B Vaccine market?
What factors are driving Meningococcal Group B Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Group B Vaccine market opportunities vary by end market size?
How does Meningococcal Group B Vaccine break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Group B Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Meningococcal Group B Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Meningococcal Group B Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Meningococcal Group B Vaccine Segment by Type
2.2.1 Bexsero
2.2.2 Trumenba
2.2.3 Other
2.3 Meningococcal Group B Vaccine Sales by Type
2.3.1 Global Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Meningococcal Group B Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Meningococcal Group B Vaccine Sale Price by Type (2019-2024)
2.4 Meningococcal Group B Vaccine Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Meningococcal Group B Vaccine Sales by Application
2.5.1 Global Meningococcal Group B Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Meningococcal Group B Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Meningococcal Group B Vaccine Sale Price by Application (2019-2024)
3 GLOBAL MENINGOCOCCAL GROUP B VACCINE BY COMPANY
3.1 Global Meningococcal Group B Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Group B Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Meningococcal Group B Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Meningococcal Group B Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Meningococcal Group B Vaccine Revenue by Company (2019-2024)
3.2.2 Global Meningococcal Group B Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Meningococcal Group B Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Group B Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Group B Vaccine Product Location Distribution
3.4.2 Players Meningococcal Group B Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL GROUP B VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Group B Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Meningococcal Group B Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Meningococcal Group B Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Meningococcal Group B Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Meningococcal Group B Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Meningococcal Group B Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Meningococcal Group B Vaccine Sales Growth
4.4 APAC Meningococcal Group B Vaccine Sales Growth
4.5 Europe Meningococcal Group B Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Group B Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Group B Vaccine Sales by Country
5.1.1 Americas Meningococcal Group B Vaccine Sales by Country (2019-2024)
5.1.2 Americas Meningococcal Group B Vaccine Revenue by Country (2019-2024)
5.2 Americas Meningococcal Group B Vaccine Sales by Type
5.3 Americas Meningococcal Group B Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Group B Vaccine Sales by Region
6.1.1 APAC Meningococcal Group B Vaccine Sales by Region (2019-2024)
6.1.2 APAC Meningococcal Group B Vaccine Revenue by Region (2019-2024)
6.2 APAC Meningococcal Group B Vaccine Sales by Type
6.3 APAC Meningococcal Group B Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Group B Vaccine by Country
7.1.1 Europe Meningococcal Group B Vaccine Sales by Country (2019-2024)
7.1.2 Europe Meningococcal Group B Vaccine Revenue by Country (2019-2024)
7.2 Europe Meningococcal Group B Vaccine Sales by Type
7.3 Europe Meningococcal Group B Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Group B Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Group B Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Meningococcal Group B Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Meningococcal Group B Vaccine Sales by Type
8.3 Middle East & Africa Meningococcal Group B Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Group B Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Group B Vaccine
10.4 Industry Chain Structure of Meningococcal Group B Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Group B Vaccine Distributors
11.3 Meningococcal Group B Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL GROUP B VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Group B Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Group B Vaccine Forecast by Region (2025-2030)
12.1.2 Global Meningococcal Group B Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Meningococcal Group B Vaccine Forecast by Type
12.7 Global Meningococcal Group B Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Meningococcal Group B Vaccine Product Portfolios and Specifications
13.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Group B Vaccine Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Meningococcal Group B Vaccine by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Meningococcal Group B Vaccine by Country/Region, 2019, 2023 & 2030
2.2 Meningococcal Group B Vaccine Segment by Type
2.2.1 Bexsero
2.2.2 Trumenba
2.2.3 Other
2.3 Meningococcal Group B Vaccine Sales by Type
2.3.1 Global Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
2.3.2 Global Meningococcal Group B Vaccine Revenue and Market Share by Type (2019-2024)
2.3.3 Global Meningococcal Group B Vaccine Sale Price by Type (2019-2024)
2.4 Meningococcal Group B Vaccine Segment by Application
2.4.1 Public
2.4.2 Private
2.5 Meningococcal Group B Vaccine Sales by Application
2.5.1 Global Meningococcal Group B Vaccine Sale Market Share by Application (2019-2024)
2.5.2 Global Meningococcal Group B Vaccine Revenue and Market Share by Application (2019-2024)
2.5.3 Global Meningococcal Group B Vaccine Sale Price by Application (2019-2024)
3 GLOBAL MENINGOCOCCAL GROUP B VACCINE BY COMPANY
3.1 Global Meningococcal Group B Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Group B Vaccine Annual Sales by Company (2019-2024)
3.1.2 Global Meningococcal Group B Vaccine Sales Market Share by Company (2019-2024)
3.2 Global Meningococcal Group B Vaccine Annual Revenue by Company (2019-2024)
3.2.1 Global Meningococcal Group B Vaccine Revenue by Company (2019-2024)
3.2.2 Global Meningococcal Group B Vaccine Revenue Market Share by Company (2019-2024)
3.3 Global Meningococcal Group B Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Group B Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Group B Vaccine Product Location Distribution
3.4.2 Players Meningococcal Group B Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL GROUP B VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Group B Vaccine Market Size by Geographic Region (2019-2024)
4.1.1 Global Meningococcal Group B Vaccine Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Meningococcal Group B Vaccine Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Meningococcal Group B Vaccine Market Size by Country/Region (2019-2024)
4.2.1 Global Meningococcal Group B Vaccine Annual Sales by Country/Region (2019-2024)
4.2.2 Global Meningococcal Group B Vaccine Annual Revenue by Country/Region (2019-2024)
4.3 Americas Meningococcal Group B Vaccine Sales Growth
4.4 APAC Meningococcal Group B Vaccine Sales Growth
4.5 Europe Meningococcal Group B Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Group B Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Group B Vaccine Sales by Country
5.1.1 Americas Meningococcal Group B Vaccine Sales by Country (2019-2024)
5.1.2 Americas Meningococcal Group B Vaccine Revenue by Country (2019-2024)
5.2 Americas Meningococcal Group B Vaccine Sales by Type
5.3 Americas Meningococcal Group B Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Group B Vaccine Sales by Region
6.1.1 APAC Meningococcal Group B Vaccine Sales by Region (2019-2024)
6.1.2 APAC Meningococcal Group B Vaccine Revenue by Region (2019-2024)
6.2 APAC Meningococcal Group B Vaccine Sales by Type
6.3 APAC Meningococcal Group B Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Group B Vaccine by Country
7.1.1 Europe Meningococcal Group B Vaccine Sales by Country (2019-2024)
7.1.2 Europe Meningococcal Group B Vaccine Revenue by Country (2019-2024)
7.2 Europe Meningococcal Group B Vaccine Sales by Type
7.3 Europe Meningococcal Group B Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Group B Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Group B Vaccine Sales by Country (2019-2024)
8.1.2 Middle East & Africa Meningococcal Group B Vaccine Revenue by Country (2019-2024)
8.2 Middle East & Africa Meningococcal Group B Vaccine Sales by Type
8.3 Middle East & Africa Meningococcal Group B Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Group B Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Group B Vaccine
10.4 Industry Chain Structure of Meningococcal Group B Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Group B Vaccine Distributors
11.3 Meningococcal Group B Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL GROUP B VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Group B Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Group B Vaccine Forecast by Region (2025-2030)
12.1.2 Global Meningococcal Group B Vaccine Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Meningococcal Group B Vaccine Forecast by Type
12.7 Global Meningococcal Group B Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Meningococcal Group B Vaccine Product Portfolios and Specifications
13.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Meningococcal Group B Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Meningococcal Group B Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Bexsero
Table 4. Major Players of Trumenba
Table 5. Major Players of Other
Table 6. Global Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 7. Global Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Table 8. Global Meningococcal Group B Vaccine Revenue by Type (2019-2024) & ($ million)
Table 9. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2019-2024)
Table 10. Global Meningococcal Group B Vaccine Sale Price by Type (2019-2024) & (USD/Unit)
Table 11. Global Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 12. Global Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Table 13. Global Meningococcal Group B Vaccine Revenue by Application (2019-2024)
Table 14. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2019-2024)
Table 15. Global Meningococcal Group B Vaccine Sale Price by Application (2019-2024) & (USD/Unit)
Table 16. Global Meningococcal Group B Vaccine Sales by Company (2019-2024) & (K Units)
Table 17. Global Meningococcal Group B Vaccine Sales Market Share by Company (2019-2024)
Table 18. Global Meningococcal Group B Vaccine Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Meningococcal Group B Vaccine Revenue Market Share by Company (2019-2024)
Table 20. Global Meningococcal Group B Vaccine Sale Price by Company (2019-2024) & (USD/Unit)
Table 21. Key Manufacturers Meningococcal Group B Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Group B Vaccine Products Offered
Table 23. Meningococcal Group B Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Meningococcal Group B Vaccine Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Meningococcal Group B Vaccine Sales Market Share Geographic Region (2019-2024)
Table 28. Global Meningococcal Group B Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Meningococcal Group B Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Meningococcal Group B Vaccine Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Meningococcal Group B Vaccine Sales Market Share by Country/Region (2019-2024)
Table 32. Global Meningococcal Group B Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Meningococcal Group B Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 35. Americas Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 36. Americas Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 38. Americas Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 39. Americas Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 40. APAC Meningococcal Group B Vaccine Sales by Region (2019-2024) & (K Units)
Table 41. APAC Meningococcal Group B Vaccine Sales Market Share by Region (2019-2024)
Table 42. APAC Meningococcal Group B Vaccine Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Meningococcal Group B Vaccine Revenue Market Share by Region (2019-2024)
Table 44. APAC Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 45. APAC Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 46. Europe Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Europe Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 48. Europe Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 50. Europe Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 51. Europe Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Meningococcal Group B Vaccine
Table 59. Key Market Challenges & Risks of Meningococcal Group B Vaccine
Table 60. Key Industry Trends of Meningococcal Group B Vaccine
Table 61. Meningococcal Group B Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Meningococcal Group B Vaccine Distributors List
Table 64. Meningococcal Group B Vaccine Customer List
Table 65. Global Meningococcal Group B Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Meningococcal Group B Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Meningococcal Group B Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Meningococcal Group B Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Meningococcal Group B Vaccine Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Meningococcal Group B Vaccine Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Meningococcal Group B Vaccine Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Meningococcal Group B Vaccine Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. GSK Basic Information, Meningococcal Group B Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Meningococcal Group B Vaccine Product Portfolios and Specifications
Table 81. GSK Meningococcal Group B Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Pfizer Basic Information, Meningococcal Group B Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Meningococcal Group B Vaccine Product Portfolios and Specifications
Table 86. Pfizer Meningococcal Group B Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 1. Meningococcal Group B Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Meningococcal Group B Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Bexsero
Table 4. Major Players of Trumenba
Table 5. Major Players of Other
Table 6. Global Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 7. Global Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Table 8. Global Meningococcal Group B Vaccine Revenue by Type (2019-2024) & ($ million)
Table 9. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2019-2024)
Table 10. Global Meningococcal Group B Vaccine Sale Price by Type (2019-2024) & (USD/Unit)
Table 11. Global Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 12. Global Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Table 13. Global Meningococcal Group B Vaccine Revenue by Application (2019-2024)
Table 14. Global Meningococcal Group B Vaccine Revenue Market Share by Application (2019-2024)
Table 15. Global Meningococcal Group B Vaccine Sale Price by Application (2019-2024) & (USD/Unit)
Table 16. Global Meningococcal Group B Vaccine Sales by Company (2019-2024) & (K Units)
Table 17. Global Meningococcal Group B Vaccine Sales Market Share by Company (2019-2024)
Table 18. Global Meningococcal Group B Vaccine Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Meningococcal Group B Vaccine Revenue Market Share by Company (2019-2024)
Table 20. Global Meningococcal Group B Vaccine Sale Price by Company (2019-2024) & (USD/Unit)
Table 21. Key Manufacturers Meningococcal Group B Vaccine Producing Area Distribution and Sales Area
Table 22. Players Meningococcal Group B Vaccine Products Offered
Table 23. Meningococcal Group B Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Meningococcal Group B Vaccine Sales by Geographic Region (2019-2024) & (K Units)
Table 27. Global Meningococcal Group B Vaccine Sales Market Share Geographic Region (2019-2024)
Table 28. Global Meningococcal Group B Vaccine Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Meningococcal Group B Vaccine Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Meningococcal Group B Vaccine Sales by Country/Region (2019-2024) & (K Units)
Table 31. Global Meningococcal Group B Vaccine Sales Market Share by Country/Region (2019-2024)
Table 32. Global Meningococcal Group B Vaccine Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Meningococcal Group B Vaccine Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 35. Americas Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 36. Americas Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 38. Americas Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 39. Americas Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 40. APAC Meningococcal Group B Vaccine Sales by Region (2019-2024) & (K Units)
Table 41. APAC Meningococcal Group B Vaccine Sales Market Share by Region (2019-2024)
Table 42. APAC Meningococcal Group B Vaccine Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Meningococcal Group B Vaccine Revenue Market Share by Region (2019-2024)
Table 44. APAC Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 45. APAC Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 46. Europe Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Europe Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 48. Europe Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 50. Europe Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 51. Europe Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 52. Middle East & Africa Meningococcal Group B Vaccine Sales by Country (2019-2024) & (K Units)
Table 53. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Meningococcal Group B Vaccine Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Meningococcal Group B Vaccine Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Meningococcal Group B Vaccine Sales by Type (2019-2024) & (K Units)
Table 57. Middle East & Africa Meningococcal Group B Vaccine Sales by Application (2019-2024) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Meningococcal Group B Vaccine
Table 59. Key Market Challenges & Risks of Meningococcal Group B Vaccine
Table 60. Key Industry Trends of Meningococcal Group B Vaccine
Table 61. Meningococcal Group B Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Meningococcal Group B Vaccine Distributors List
Table 64. Meningococcal Group B Vaccine Customer List
Table 65. Global Meningococcal Group B Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 66. Global Meningococcal Group B Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 68. Americas Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Meningococcal Group B Vaccine Sales Forecast by Region (2025-2030) & (K Units)
Table 70. APAC Meningococcal Group B Vaccine Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 72. Europe Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Meningococcal Group B Vaccine Sales Forecast by Country (2025-2030) & (K Units)
Table 74. Middle East & Africa Meningococcal Group B Vaccine Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Meningococcal Group B Vaccine Sales Forecast by Type (2025-2030) & (K Units)
Table 76. Global Meningococcal Group B Vaccine Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Meningococcal Group B Vaccine Sales Forecast by Application (2025-2030) & (K Units)
Table 78. Global Meningococcal Group B Vaccine Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. GSK Basic Information, Meningococcal Group B Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Meningococcal Group B Vaccine Product Portfolios and Specifications
Table 81. GSK Meningococcal Group B Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Pfizer Basic Information, Meningococcal Group B Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer Meningococcal Group B Vaccine Product Portfolios and Specifications
Table 86. Pfizer Meningococcal Group B Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
LIST OF FIGURES
Figure 1. Picture of Meningococcal Group B Vaccine
Figure 2. Meningococcal Group B Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Group B Vaccine Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Meningococcal Group B Vaccine Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Meningococcal Group B Vaccine Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Bexsero
Figure 10. Product Picture of Trumenba
Figure 11. Product Picture of Other
Figure 12. Global Meningococcal Group B Vaccine Sales Market Share by Type in 2023
Figure 13. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2019-2024)
Figure 14. Meningococcal Group B Vaccine Consumed in Public
Figure 15. Global Meningococcal Group B Vaccine Market: Public (2019-2024) & (K Units)
Figure 16. Meningococcal Group B Vaccine Consumed in Private
Figure 17. Global Meningococcal Group B Vaccine Market: Private (2019-2024) & (K Units)
Figure 18. Global Meningococcal Group B Vaccine Sales Market Share by Application (2023)
Figure 19. Global Meningococcal Group B Vaccine Revenue Market Share by Application in 2023
Figure 20. Meningococcal Group B Vaccine Sales Market by Company in 2023 (K Units)
Figure 21. Global Meningococcal Group B Vaccine Sales Market Share by Company in 2023
Figure 22. Meningococcal Group B Vaccine Revenue Market by Company in 2023 ($ Million)
Figure 23. Global Meningococcal Group B Vaccine Revenue Market Share by Company in 2023
Figure 24. Global Meningococcal Group B Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 25. Global Meningococcal Group B Vaccine Revenue Market Share by Geographic Region in 2023
Figure 26. Americas Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 27. Americas Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 28. APAC Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 29. APAC Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 30. Europe Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 31. Europe Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 32. Middle East & Africa Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 33. Middle East & Africa Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 34. Americas Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 35. Americas Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 36. Americas Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 37. Americas Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 38. United States Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 39. Canada Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 40. Mexico Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 41. Brazil Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 42. APAC Meningococcal Group B Vaccine Sales Market Share by Region in 2023
Figure 43. APAC Meningococcal Group B Vaccine Revenue Market Share by Regions in 2023
Figure 44. APAC Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 45. APAC Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 46. China Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 47. Japan Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 48. South Korea Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 49. Southeast Asia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 50. India Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 51. Australia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 52. China Taiwan Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 53. Europe Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 54. Europe Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 55. Europe Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 56. Europe Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 57. Germany Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 58. France Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 59. UK Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 60. Italy Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 61. Russia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 62. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 63. Middle East & Africa Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 64. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 65. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 66. Egypt Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 67. South Africa Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 68. Israel Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 69. Turkey Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 70. GCC Country Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Meningococcal Group B Vaccine in 2023
Figure 72. Manufacturing Process Analysis of Meningococcal Group B Vaccine
Figure 73. Industry Chain Structure of Meningococcal Group B Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Meningococcal Group B Vaccine Sales Market Forecast by Region (2025-2030)
Figure 76. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Region (2025-2030)
Figure 77. Global Meningococcal Group B Vaccine Sales Market Share Forecast by Type (2025-2030)
Figure 78. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Type (2025-2030)
Figure 79. Global Meningococcal Group B Vaccine Sales Market Share Forecast by Application (2025-2030)
Figure 80. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Meningococcal Group B Vaccine
Figure 2. Meningococcal Group B Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Group B Vaccine Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Meningococcal Group B Vaccine Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Meningococcal Group B Vaccine Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Bexsero
Figure 10. Product Picture of Trumenba
Figure 11. Product Picture of Other
Figure 12. Global Meningococcal Group B Vaccine Sales Market Share by Type in 2023
Figure 13. Global Meningococcal Group B Vaccine Revenue Market Share by Type (2019-2024)
Figure 14. Meningococcal Group B Vaccine Consumed in Public
Figure 15. Global Meningococcal Group B Vaccine Market: Public (2019-2024) & (K Units)
Figure 16. Meningococcal Group B Vaccine Consumed in Private
Figure 17. Global Meningococcal Group B Vaccine Market: Private (2019-2024) & (K Units)
Figure 18. Global Meningococcal Group B Vaccine Sales Market Share by Application (2023)
Figure 19. Global Meningococcal Group B Vaccine Revenue Market Share by Application in 2023
Figure 20. Meningococcal Group B Vaccine Sales Market by Company in 2023 (K Units)
Figure 21. Global Meningococcal Group B Vaccine Sales Market Share by Company in 2023
Figure 22. Meningococcal Group B Vaccine Revenue Market by Company in 2023 ($ Million)
Figure 23. Global Meningococcal Group B Vaccine Revenue Market Share by Company in 2023
Figure 24. Global Meningococcal Group B Vaccine Sales Market Share by Geographic Region (2019-2024)
Figure 25. Global Meningococcal Group B Vaccine Revenue Market Share by Geographic Region in 2023
Figure 26. Americas Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 27. Americas Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 28. APAC Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 29. APAC Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 30. Europe Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 31. Europe Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 32. Middle East & Africa Meningococcal Group B Vaccine Sales 2019-2024 (K Units)
Figure 33. Middle East & Africa Meningococcal Group B Vaccine Revenue 2019-2024 ($ Millions)
Figure 34. Americas Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 35. Americas Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 36. Americas Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 37. Americas Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 38. United States Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 39. Canada Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 40. Mexico Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 41. Brazil Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 42. APAC Meningococcal Group B Vaccine Sales Market Share by Region in 2023
Figure 43. APAC Meningococcal Group B Vaccine Revenue Market Share by Regions in 2023
Figure 44. APAC Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 45. APAC Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 46. China Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 47. Japan Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 48. South Korea Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 49. Southeast Asia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 50. India Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 51. Australia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 52. China Taiwan Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 53. Europe Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 54. Europe Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 55. Europe Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 56. Europe Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 57. Germany Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 58. France Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 59. UK Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 60. Italy Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 61. Russia Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 62. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Country in 2023
Figure 63. Middle East & Africa Meningococcal Group B Vaccine Revenue Market Share by Country in 2023
Figure 64. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Type (2019-2024)
Figure 65. Middle East & Africa Meningococcal Group B Vaccine Sales Market Share by Application (2019-2024)
Figure 66. Egypt Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 67. South Africa Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 68. Israel Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 69. Turkey Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 70. GCC Country Meningococcal Group B Vaccine Revenue Growth 2019-2024 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Meningococcal Group B Vaccine in 2023
Figure 72. Manufacturing Process Analysis of Meningococcal Group B Vaccine
Figure 73. Industry Chain Structure of Meningococcal Group B Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Meningococcal Group B Vaccine Sales Market Forecast by Region (2025-2030)
Figure 76. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Region (2025-2030)
Figure 77. Global Meningococcal Group B Vaccine Sales Market Share Forecast by Type (2025-2030)
Figure 78. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Type (2025-2030)
Figure 79. Global Meningococcal Group B Vaccine Sales Market Share Forecast by Application (2025-2030)
Figure 80. Global Meningococcal Group B Vaccine Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Biomedical Refrigerators Market Growth 2025-2031
US$ 3,660.00
March 2025
136 pages
Global Medical Linear Accelerator Market Growth 2025-2031
US$ 3,660.00
December 2024
80 pages
Global Nasopharyngeal Swabs Market Growth 2023-2029
US$ 3,660.00
February 2023
95 pages
Global Disposable Laryngeal Mask Market Growth 2024-2030
US$ 3,660.00
June 2024
120 pages
Global Digital Dental Radiography Systems Market Growth 2024-2030
US$ 3,660.00
November 2024
132 pages
